Esperion Therapeutics Loss Widens

(RTTNews) - Esperion Therapeutics Inc. (ESPR) Monday reported second-quarter net loss of $7 million or $19.82 per share, compared with net loss of $3 million or $9.94 per share last year.

Esperion, a clinical stage biopharmaceutical company, has not recorded revenues.

Looking ahead, the company expects that its cash and cash equivalents will be about $75 million at December 31, 2013. The company believes that existing cash resources will fund it until at least the end of 2015. Full-year 2013 net cash used in operating activities is expected to be about $25 million.